Display options
Cite
Luna-Dulcey L, Almada da Silva J, Jimenez-Renard V, et al. [6]-Gingerol-Derived Semi-Synthetic Compound SSi6 Inhibits Tumor Growth and Metastatic Dissemination in Triple-Negative Breast Cancer Xenograft Models. Cancers (Basel). 2021;13(12)doi: 10.3390/cancers13122855.
Luna-Dulcey, L., Almada da Silva, J., Jimenez-Renard, V., Caleiras, E., Mouron, S., Quintela-Fandino, M., & Cominetti, M. R. (2021). [6]-Gingerol-Derived Semi-Synthetic Compound SSi6 Inhibits Tumor Growth and Metastatic Dissemination in Triple-Negative Breast Cancer Xenograft Models. Cancers, 13(12), . https://doi.org/10.3390/cancers13122855
Luna-Dulcey, Liany, et al. "[6]-Gingerol-Derived Semi-Synthetic Compound SSi6 Inhibits Tumor Growth and Metastatic Dissemination in Triple-Negative Breast Cancer Xenograft Models." Cancers vol. 13,12 (2021). doi: https://doi.org/10.3390/cancers13122855
Luna-Dulcey L, Almada da Silva J, Jimenez-Renard V, Caleiras E, Mouron S, Quintela-Fandino M, Cominetti MR. [6]-Gingerol-Derived Semi-Synthetic Compound SSi6 Inhibits Tumor Growth and Metastatic Dissemination in Triple-Negative Breast Cancer Xenograft Models. Cancers (Basel). 2021 Jun 08;13(12). doi: 10.3390/cancers13122855. PMID: 34201040; PMCID: PMC8228746.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Jun 08;13(12). doi: 10.3390/cancers13122855.

[6]-Gingerol-Derived Semi-Synthetic Compound SSi6 Inhibits Tumor Growth and Metastatic Dissemination in Triple-Negative Breast Cancer Xenograft Models.

Cancers

Liany Luna-Dulcey, James Almada da Silva, Veronica Jimenez-Renard, Eduardo Caleiras, Silvana Mouron, Miguel Quintela-Fandino, Marcia R Cominetti

Affiliations

  1. Laboratory of Biology of Aging (LABEN), Department of Gerontology, Federal University of São Carlos (UFSCar), CEP 13565-905 São Carlos-SP, Brazil.
  2. Department of Pharmacy, Federal University of Sergipe (UFS), CEP 49400-000, Av. Gov. Marcelo Deda, 330-São José, Lagarto-SE, Brazil.
  3. Breast Cancer Clinical Research Unit, Spanish National Cancer Research Center (CNIO), CP 28029 Madrid, Spain.
  4. Histopathology Unit, Spanish National Cancer Research Center (CNIO), CP 28029 Madrid, Spain.

PMID: 34201040 PMCID: PMC8228746 DOI: 10.3390/cancers13122855

Abstract

Breast cancer metastasis is the most common cause of cancer death in women worldwide. Triple-negative breast cancers (TNBC) form a heterogeneous group of tumors that have higher relapse rates and poorer survival compared to other breast cancer subtypes. Thus, this work reports the antitumor and antimetastatic activities of a [6]-gingerol-derived semi-synthetic compound named SSi6 on MDA-MB-231 TNBC cells using xenograft models. SSi6 did not cause toxic effects

Keywords: [6]-gingerol; acute toxicity; metastatic progression; semi-synthetic compound; triple-negative breast cancer; xenograft model

References

  1. J Pathol. 2005 Jan;205(2):275-92 - PubMed
  2. CA Cancer J Clin. 2020 Jan;70(1):7-30 - PubMed
  3. Anticancer Drugs. 2020 Jan;31(1):35-43 - PubMed
  4. Signal Transduct Target Ther. 2020 Mar 12;5(1):28 - PubMed
  5. World J Stem Cells. 2019 Sep 26;11(9):594-603 - PubMed
  6. Oncotarget. 2017 Jan 31;8(5):8693-8706 - PubMed
  7. Cancer Res. 2017 Apr 1;77(7):1548-1552 - PubMed
  8. Oncotarget. 2017 Aug 10;8(42):72260-72271 - PubMed
  9. Cancer Chemother Pharmacol. 2020 Feb;85(2):379-390 - PubMed
  10. Cell Oncol (Dordr). 2020 Oct;43(5):915-929 - PubMed
  11. Curr Cancer Drug Targets. 2006 Aug;6(5):365-84 - PubMed
  12. Exp Cell Res. 2018 Mar 15;364(2):243-251 - PubMed
  13. Clin Breast Cancer. 2020 Feb;20(1):e20-e26 - PubMed
  14. Oncotarget. 2018 Jul 20;9(56):30787-30804 - PubMed
  15. Adv Anat Pathol. 2020 Jan;27(1):27-35 - PubMed
  16. Anticancer Agents Med Chem. 2017;17(2):152-163 - PubMed
  17. Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1319-39 - PubMed
  18. Curr Top Med Chem. 2020;20(2):161-169 - PubMed
  19. Toxicol Rep. 2015 Jul 17;2:1086-1100 - PubMed
  20. Nat Commun. 2018 Aug 29;9(1):3501 - PubMed
  21. Food Chem Toxicol. 2008 Feb;46(2):409-20 - PubMed
  22. Surgery. 2018 Feb;163(2):330-335 - PubMed
  23. Eur J Cancer. 2009 Sep;45 Suppl 1:27-40 - PubMed
  24. Lancet. 2018 Sep 22;392(10152):1072-1088 - PubMed
  25. Oncotarget. 2015 Dec 22;6(41):43310-25 - PubMed
  26. Front Endocrinol (Lausanne). 2018 Aug 28;9:492 - PubMed
  27. Clin Oncol (R Coll Radiol). 2011 Nov;23(9):587-600 - PubMed
  28. Oncol Rep. 2018 May;39(5):2252-2260 - PubMed
  29. J Basic Clin Pharm. 2016 Mar;7(2):27-31 - PubMed
  30. Yonsei Med J. 2013 Sep;54(5):1168-77 - PubMed
  31. Sci Rep. 2020 Jun 2;10(1):8964 - PubMed
  32. Expert Opin Pharmacother. 2016;17(1):1-5 - PubMed
  33. Ann Oncol. 2011 Jun;22(6):1288-1294 - PubMed
  34. J Pharm Bioallied Sci. 2014 Apr;6(2):69-80 - PubMed
  35. Molecules. 2007 Aug 17;12(8):1910-39 - PubMed
  36. Adv Exp Med Biol. 2019;1152:311-334 - PubMed
  37. Lancet. 2016 Oct 8;388(10053):1459-1544 - PubMed
  38. J Biochem Mol Toxicol. 2019 Dec;33(12):e22403 - PubMed
  39. Cell Rep. 2016 Jun 21;15(12):2705-18 - PubMed
  40. Mol Nutr Food Res. 2014 Feb;58(2):256-66 - PubMed
  41. Cancer Treat Rev. 2018 Jul;68:102-110 - PubMed
  42. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  43. J Exp Clin Cancer Res. 2019 Jul 2;38(1):285 - PubMed

Publication Types

Grant support